Elsevier

Journal of Controlled Release

Volume 320, 10 April 2020, Pages 314-327
Journal of Controlled Release

Ligand-installed anti-VEGF genomic nanocarriers for effective gene therapy of primary and metastatic tumors

https://doi.org/10.1016/j.jconrel.2020.01.026Get rights and content

Abstract

The systemic dosage regimen exhibited low therapeutic efficacy and incurred severe adverse effect, thus, the development of tumor-targeted therapeutics is crucial important for tumor precision therapy. Herein, the active targeted modulation of tumor microenvironments was schemed by developing hyaluronic acid-installed genomic nanocarriers (HA-NPs) for effectively ablation of both primary and metastatic tumors through anti-vascular endothelial growth factor (anti-VEGF) approach. The anti-VEGF genomic payloads were strategically packaged into the well-defined synthetic nanocarriers by layer-by-layer preparation strategy, exhibiting high colloidal stability and much lower cell viability than the cationic gene carriers. Besides, the HA-NPs could specifically and efficiently internalize with cancer cells for efficient intracellular gene delivery, leading to high gene transfection efficacy. Moreover, it further demonstrated efficient extravasation, high accumulation and deep penetration in tumors, which markedly facilitated tumor-targeted expression of anti-VEGF genomic payloads for inhabitation of neo-vasculature, consecutively contributing to potent ablation of solid tumors. In addition, the ligand-installed nanocarriers facilitated systemic treatment of melanoma lung metastasis by the expressed anti-VEGF proteins, which were extensively spread along blood circulation and metastatic niches to diminish the formation of neovasculature for tumorigenesis. Therefore, the proposed anti-VEGF genomic nanocarriers could shed intriguing implication in effectively treatment of primary tumors and metastasis.

Introduction

The nucleic acid-based therapeutics have imparted important implications in treatment of a staggering spectrum of diseases, for instance, cancer [[1], [2], [3]], tissue regeneration [4], cardiovascular diseases [5], hypertension [6] and age-related macular degeneration [7], etc. Nonetheless, the genomic therapeutics are susceptible to enzymatic degradation by nucleases in biological milieu and unable to escape from endosome for entering targeted cells, which requires gene delivery vehicles [8,9]. The therapeutic genomic codes are expected to be delivered to diseased sites in pursuit of functional proteins expression in the targeted cells [10]. Compared to viral vectors, the synthetic gene carriers, especially the cationic materials formulated ones [11], such as polyethyleneimine (PEI) [12,13], dendritic polyamidoamine (PAMAM) [14,15], chitosan [16,17] and cationic liposomes [18,19], have implied their facile utilities in forming nanoscale gene condensates through electrostatic interactions, and exhibited remarkable in vitro gene expression activities in the affected cells. Despite of the tempting function of non-viral gene vehicles, the inadequate in vivo transfection activity particularly administrated through systemic route, as well as potential toxicity of the indispensable cationic compositions, impeded the clinical translation of conventional cationic gene carriers [[20], [21], [22]]. However, towards systemic administrations, the non-specific reactions during blood retention have to be minimized, as the cationic gene vehicles were easily to be cleared by immune systems, for instance, the reticuloendothelial systems (RES) [23]. Besides, recent study has also uncovered that the cationic polymer/gene complexes were likely to be accumulated and disassembled in the glomerular basement membrane (GBM) in kidney, and rapidly eliminated from the circulation [24]. Therefore, a general strategy is to shelter underneath protective shells, e.g., poly(ethylene glycol) (PEG), on to the cationic gene carriers for achieving stealth effect, preventing interaction or destabilization by other biological species, e.g., enzymes, and extending retention in blood circulation [[25], [26], [27], [28]]. Nonetheless, the PEGylation substantially reduced the internalization between PEGylated gene vehicles and cancer cells [29]. The low cellular uptake by cancer cells and scavenging by non-targeted cells, are major barriers for the PEGylated cationic gene vehicles, which may lead to therapeutic failure. In addition, the PEGylated gene vehicles are mainly passively accumulated in tumors through the enhanced permeability retention (EPR) effects [30], which could be difficult for targeting tumors that are poorly vascularized or without EPR effects, e.g., small metastatic tumors [31]. Therefore, the development of biocompatible gene delivery vehicles that are capable of specifically internalization with cancer cells for efficient gene delivery is imperative to realize the gene therapeutics towards effective and precision therapy [32].

Herein, we developed novel ligand-installed nanocarriers through a layer-by-layer preparation strategy for efficient gene delivery, and effective gene therapy of primary and metastatic tumors through the anti-VEGF approach (Scheme 1). The nanocarriers were innovated by using the biodegradable polycationic polymer, poly{N-[N′-(2-aminoethyl)-2-aminoethyl]aspartamide} [PAsp(DET)] to formulate cationic PAsp(DET)/pDNA condensates by electrostatic interactions, and then attaching the biocompatible glycosaminoglycan layer of HA on the surface of HA-NPs (Scheme 1A). The PAsp(DET) facilitates condensation of pDNA into nanoscale and endosome escape [33,34], while the HA could selectively internalize with CD44 receptors overexpressed on cancer cells and tumor vascular endothelial cells to prompt preferential intracellular delivery of pDNA payloads into cancer cells [[35], [36], [37]], and block the CD44-angiogenic signaling for pursuit of inhibited tumorigenesis [[38], [39], [40], [41]]. As VEGF is critical for tumor angiogenesis and anti-angiogenesis is an effective approach for controlling tumor growth and development, hence, it is readily envisioned that the targeted HA transportation into tumors would render anti-VEGF tumor microenvironment. Herein, the pDNA encoding soluble VEGF receptor 1 (VEGFR1) that also referred as the soluble fms-like tyrosine kinase-1 (sFlt-1), was employed as the genomic payload to construct anti-tumor therapeutics. The sFlt-1 expressed at the tumor microenvironments is assumed to exert anti-VEGF efficacy for suppression of neovasculature formation, and the sFlt-1diffused into the circulatory system forms anti-VEGF environment to actively silence the signal of angiogenetic VEGF molecules wherever VEGF was abundant, consequently eliciting inhibitory potency to both primary and metastatic tumors (Scheme 1B). The innovated nanocarriers highly decreased the toxicity of cationic polymer-based gene carriers, improved cancer cell-targeting ability, promoted the intracellular gene delivery and gene transfection efficacy, demonstrated high accumulation and deep penetration in tumors, which finally lead to effective ablation of primary and metastatic tumors with expressed high levels of sFlt-1 and anti-angiogenetic effect.

Section snippets

Materials and animals

α-Benzyl-l-aspartate N-carboxy anhydride (BLA-NCA) was purchased from Chengdu Enlai Biological Technology Co., Ltd. (Chengdu, China). Methoxy-PEG-amine (mPEG-NH2) (Mw = 10 kDa) was purchased from SinoPEG Co. (Xiamen, China). HA (Mw = 5, 37, 89, 111 and 230 kDa) was purchased from Bloomaga Freda Biopharm Co. Ltd. (Jinan, China). Diethylenetriamine (DET), N-methyl pyrrolidone (NMP), 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride (EDC) were purchased from Adamas Reagent Co. Ltd.

Preparation and characterization of nanocarriers

The PAsp(DET) homopolymer and PEG-b-PAsp(DET) block copolymer with similar number of units were successfully synthesized through n-butylamine and methoxy-PEG-NH2 initiated ring-opening polymerization of BLA-NCA, followed by aminolysis reaction with DET (Fig. S3,4) [42,43]. Firstly, the cationic pDNA/PAsp(DET) condensates (PAD-NPs) were formulated through the electrostatic interactions (Scheme 1A). The PAD-NPs with different N/P ratio (amine groups in polymer/phosphate groups in pDNA) ranging

Conclusion

In the present study, we have elaborated a tumor-targeted gene delivery system, whose surface was functionalized with anionic biocompatible glycosaminoglycan of HA. Aside from the improved biocompatibility, with reference to the specific affinity of HA to CD44 receptors overexpressed on cancerous cells, the proposed delivery systems have managed to harness HA as the targeting motif for promoted tumor accumulation and cellular internalization with targeted cancer cells. Subsequent anti-tumor

Declaration of Competing Interest

The authors declare no competing financial interest.

Acknowledgements

This research was funded by the National Key R&D Program of China (2017YFA0207900), the Recruitment Program of Global Experts (D1424002A) and the Sichuan Science and Technology Program (2018RZ0134).

References (57)

  • Z. Ge et al.

    Targeted gene delivery by polyplex micelles with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors

    Biomaterials

    (2014)
  • G. Cao et al.

    Involvement of endothelial CD44 during in vivo angiogenesis

    Am. J. Pathol.

    (2006)
  • M. Tremmel et al.

    A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis

    Blood

    (2009)
  • P. Zhang et al.

    CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells

    FEBS Lett.

    (2014)
  • P. Mi et al.

    Gd-DTPA-loaded polymer-metal complex micelles with high relaxivity for MR cancer imaging

    Biomaterials

    (2013)
  • Q. Chen et al.

    Homo-catiomer integration into PEGylated polyplex micelle from block-catiomer for systemic anti-angiogenic gene therapy for fibrotic pancreatic tumors

    Biomaterials

    (2012)
  • P. Mi et al.

    Block copolymer-boron cluster conjugate for effective boron neutron capture therapy of solid tumors

    J. Control. Release

    (2017)
  • F. Dosio et al.

    Hyaluronic acid for anticancer drug and nucleic acid delivery

    Adv. Drug Deliv. Rev.

    (2016)
  • G. Huang et al.

    Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system

    J. Control. Release

    (2018)
  • V. Jeannot et al.

    Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer

    J. Control. Release

    (2018)
  • K. Itaka et al.

    Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity

    Biomaterials

    (2010)
  • H.J. Park et al.

    Nonviral delivery of genetic medicine for therapeutic angiogenesis

    Adv. Drug Deliv. Rev.

    (2012)
  • K. Miyata et al.

    Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses

    Chem. Soc. Rev.

    (2012)
  • C. Chu et al.

    Zinc(II)-Dipicolylamine coordination nanotheranostics: toward synergistic nanomedicine by combined photo/gene therapy

    Angew. Chem. Int. Ed.

    (2019)
  • T. Nomoto et al.

    Three-layered polyplex micelle as a multifunctional nanocarrier platform for light-induced systemic gene transfer

    Nat. Commun.

    (2014)
  • M. Cucchiarini et al.

    Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair

    Nat. Rev. Rheumatol.

    (2019)
  • J.J. Nie et al.

    Unlockable nanocomplexes with self-accelerating nucleic acid release for effective staged gene therapy of cardiovascular diseases

    Adv. Mater.

    (2018)
  • Y.Q. Wang et al.

    Delivery of therapeutic AGT shRNA by PEG-Bu for hypertension therapy

    PLoS One

    (2013)
  • Cited by (19)

    • α-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery

      2021, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Moreover, HA could also shield the positive charges of the polyplexes to improve the stability and circulation of polyplexes in the blood, and it can also reduce the toxicity associated with the cationic polymers. In a subcutaneous B16F10 tumor murine model, the HA-coated polyplexes containing sFlt-1 pDNA achieved excellent tumor growth suppression efficiency, outperforming the un-coated polyplexes [122]. PEGylation or polyanion-based surface decoration of nano-vehicles can greatly contribute to the enhanced serum stability, while at the meantime, compromises the interactions of nano-vehicles with cell membranes to diminish the cellular internalization level.

    • Transform nanomedicine with breakthrough thinking?

      2021, Journal of Controlled Release
    • Targeted-delivery of siRNA via a polypeptide-modified liposome for the treatment of gp96 over-expressed breast cancer

      2021, Materials Science and Engineering C
      Citation Excerpt :

      The distribution of FAM-siRNA in the organs was detected by an in-vivo imaging system (Maestro, Woburn, MA, USA). The fluorescence intensity in organs was analyzed using Carestream Molecular Imaging Software [20]. Antitumor activity of siSuvi transfected by liposomes was investigated using xenograft model in mice.

    • Tumor angiogenesis: Current challenges and therapeutic opportunities

      2021, Cancer Treatment and Research Communications
      Citation Excerpt :

      In a variety of ways, angiogenesis inhibitors function by limiting or suppressing the formation of new blood vessels and interfering with various stages of development process [69]. Mostly, these inhibitors are molecules of the monoclonal antibody, which in turn recognize the VEGF to bind and then play its significant role in inhibiting and reducing its activity [70]. Thus, after these inhibitory drugs bind to VEGF, it then becomes unable to activate its own receptors on the surface of ECs.

    View all citing articles on Scopus
    1

    H. Zhang and 1J. Liu contributed equally to this work.

    View full text